Shingo Kuroda

552 total citations
27 papers, 441 citations indexed

About

Shingo Kuroda is a scholar working on Molecular Biology, Rheumatology and Oncology. According to data from OpenAlex, Shingo Kuroda has authored 27 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Rheumatology and 5 papers in Oncology. Recurrent topics in Shingo Kuroda's work include Bone and Dental Protein Studies (7 papers), dental development and anomalies (5 papers) and Diabetes Treatment and Management (5 papers). Shingo Kuroda is often cited by papers focused on Bone and Dental Protein Studies (7 papers), dental development and anomalies (5 papers) and Diabetes Treatment and Management (5 papers). Shingo Kuroda collaborates with scholars based in Japan, Canada and United States. Shingo Kuroda's co-authors include Kohei Kaku, Rima Wazen, Pierre Moffatt, Antonio Nanci, Nobuya Inagaki, Clarice Nishio, Hiroki Sano, Nagato Tamamura, Teruko Takano‐Yamamoto and Yuichi Sakai and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Journal of Dental Research.

In The Last Decade

Shingo Kuroda

26 papers receiving 439 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shingo Kuroda Japan 11 214 132 126 76 51 27 441
Yongqian Jia China 13 343 1.6× 34 0.3× 26 0.2× 137 1.8× 7 0.1× 43 587
Nanor Sirab France 10 274 1.3× 88 0.7× 72 0.6× 94 1.2× 179 3.5× 14 628
Xue Yu China 8 95 0.4× 17 0.1× 131 1.0× 17 0.2× 5 0.1× 22 465
M. Aalto Finland 13 67 0.3× 36 0.3× 42 0.3× 22 0.3× 13 0.3× 32 365
Zhikang Cai China 16 197 0.9× 58 0.4× 178 1.4× 74 1.0× 277 5.4× 43 640
Hyun Chul Chung South Korea 11 148 0.7× 34 0.3× 77 0.6× 69 0.9× 80 1.6× 37 502
Marika Bergenstock United States 6 330 1.5× 17 0.1× 41 0.3× 231 3.0× 9 0.2× 8 581
Ralph H. Starkey United States 7 193 0.9× 96 0.7× 25 0.2× 101 1.3× 5 0.1× 8 504
Y. Horn Israel 12 117 0.5× 52 0.4× 26 0.2× 120 1.6× 13 0.3× 57 431
Barbara Ruszkowska-Ciastek Poland 10 106 0.5× 48 0.4× 12 0.1× 64 0.8× 5 0.1× 44 354

Countries citing papers authored by Shingo Kuroda

Since Specialization
Citations

This map shows the geographic impact of Shingo Kuroda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shingo Kuroda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shingo Kuroda more than expected).

Fields of papers citing papers by Shingo Kuroda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shingo Kuroda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shingo Kuroda. The network helps show where Shingo Kuroda may publish in the future.

Co-authorship network of co-authors of Shingo Kuroda

This figure shows the co-authorship network connecting the top 25 collaborators of Shingo Kuroda. A scholar is included among the top collaborators of Shingo Kuroda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shingo Kuroda. Shingo Kuroda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Song, Zhiqiang, Qin Du, Guoxin Zhang, et al.. (2025). Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study. Chinese Medical Journal. 138(22). 2938–2946. 2 indexed citations
2.
Kato, Naoya, Masatoshi Kudo, Kaoru Tsuchiya, et al.. (2023). Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study. Hepatology Research. 53(5). 409–416. 3 indexed citations
3.
4.
Nakaigawa, Noboru, Yoshihiko Tomita, Satoshi Tamada, et al.. (2023). Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. International Journal of Clinical Oncology. 28(3). 416–426. 3 indexed citations
5.
Kudo, Masatoshi, Kaoru Tsuchiya, Naoya Kato, et al.. (2021). Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. Journal of Gastroenterology. 56(2). 181–190. 13 indexed citations
6.
Tomita, Yoshihiko, Katsunori Tatsugami, Noboru Nakaigawa, et al.. (2020). Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients. International Journal of Urology. 27(11). 952–959. 22 indexed citations
7.
Oya, Mototsugu, Satoshi Tamada, Katsunori Tatsugami, et al.. (2020). A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology. 38(15_suppl). 5089–5089. 5 indexed citations
8.
Radford, John, Joseph M. Connors, Anas Younes, et al.. (2019). EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematological Oncology. 37(S2). 290–291.
9.
Ito, Sadayoshi, et al.. (2019). Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria. Clinical Journal of the American Society of Nephrology. 14(3). 354–363. 4 indexed citations
10.
Yasu, Takeo, et al.. (2019). A case of under-dosing after raltegravir formulation change in an elderly patient treated for HIV.. PubMed. 74(1). 62–63. 1 indexed citations
11.
12.
Inagaki, Nobuya, et al.. (2015). Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. The Lancet Diabetes & Endocrinology. 3(3). 191–197. 72 indexed citations
13.
Wazen, Rima, et al.. (2015). Inactivation of the Odontogenic ameloblast-associated gene affects the integrity of the junctional epithelium and gingival healing. European Cells and Materials. 30. 187–199. 32 indexed citations
14.
15.
Inagaki, Nobuya, et al.. (2013). SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 2(2). 125–132. 43 indexed citations
16.
Wazen, Rima, et al.. (2012). Odontogenic ameloblast-associated and amelotin are novel basal lamina components. Histochemistry and Cell Biology. 137(3). 329–338. 49 indexed citations
17.
Kuroda, Shingo, et al.. (2011). Ameloblastin is not implicated in bone remodelling and repair. European Cells and Materials. 22. 56–67. 6 indexed citations
18.
Nishio, Clarice, Rima Wazen, Shingo Kuroda, Pierre Moffatt, & Antonio Nanci. (2011). P44-expression pattern of APIN and amelotin during formation and regeneration of the junctional epithelium.. PubMed. 49(3). 111–2. 3 indexed citations
19.
Nishio, Clarice, Rima Wazen, Shingo Kuroda, Pierre Moffatt, & Antonio Nanci. (2010). Expression pattern of odontogenic ameloblast-associated and amelotin during formation and regeneration of the junctional epithelium. European Cells and Materials. 20. 393–402. 62 indexed citations
20.
Kuroda, Shingo, et al.. (2005). Expression of osteopontin mRNA in odontoclasts revealed by in situ hybridization during experimental tooth movement in mice. Journal of Bone and Mineral Metabolism. 23(2). 110–113. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yongqian Jia Breakdown of academic impact, for papers by Nanor Sirab Breakdown of academic impact, for papers by Xue Yu Breakdown of academic impact, for papers by M. Aalto Breakdown of academic impact, for papers by Zhikang Cai Breakdown of academic impact, for papers by Hyun Chul Chung Breakdown of academic impact, for papers by Marika Bergenstock Breakdown of academic impact, for papers by Ralph H. Starkey Breakdown of academic impact, for papers by Y. Horn Breakdown of academic impact, for papers by Barbara Ruszkowska-Ciastek
Rankless by CCL
2026